alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 326–350 of 502 studies published 2020 · free to read (page 14 of 21) · 30,580 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,054 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The impact of nutrition on COVID-19 susceptibility and long-term consequences

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Brain, behavior, and immunity 2020-04-18

While all groups are affected by the COVID-19 pandemic, the elderly, underrepresented minorities, and those with underlying medical conditions are at the greatest risk. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Potential Benefits of Physical Activity in MCI and Dementia

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Behavioural neurology 2020-02-12

Physical activity improves overall health and reduces the risk of many negative health outcomes and may be effective in improving cognition, independent functioning, and psychological health in older adults. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Stressful Life Events and Racial Disparities in Cognition Among Middle-Aged and Older Adults

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Journal of Alzheimer's disease : JAD 2020-01-01

Greater lifetime stress predicted poorer later-life cognition, and, in a small sample of African Americans, faster declines in a key domain of episodic memory. 4 key findings →

Participants: 50 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Dementia care and COVID-19 pandemic: a necessary digital revolution

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2020-06-17

Due to the COVID-19 pandemic, most memory clinics have had to suspend their activities. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

IoT Wearable Sensors and Devices in Elderly Care: A Literature Review

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Sensors (Basel, Switzerland) 2020-05-16

The increasing ageing global population is causing an upsurge in ailments related to old age, primarily dementia and Alzheimer's disease, frailty, Parkinson's, and cardiovascular disease, but also a general need for general eldercare as well as active and healthy ageing. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Predicting Cognitive Impairment and Dementia: A Machine Learning Approach

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Journal of Alzheimer's disease : JAD 2020-01-01

Higher-order factors (e.g., emotional distress, subjective health), which reflect complex interactions between various aspects of an individual, were more important than narrowly defined factors (e.g., clinical and behavioral indicators) when evaluated concurrently to predict cognitive impairment and dementia. 2 key findings →

Design: post-hoc analysis Participants: 9,979 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Classifications of Neurodegenerative Disorders Using a Multiplex Blood Biomarkers-Based Machine Learning Model

✓ Peer-reviewed alzhub usefulness score 49 out of 100. International journal of molecular sciences 2020-09-21

Easily accessible biomarkers for Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal dementia (FTD), and related neurodegenerative disorders are urgently needed in an aging society to assist early-stage diagnoses. 4 key findings →

Participants: 377 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Depression, Anxiety, and Apathy in Mild Cognitive Impairment: Current Perspectives

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Frontiers in aging neuroscience 2020-01-30

MCI patients have a high prevalence of depression/anxiety/apathy; furthermore, patients with MCI and concomitant depression/anxiety/apathy have more pronounced cognitive deficits and progress more often to dementia than MCI patients without depression/anxiety/apathy. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multi-View Separable Pyramid Network for AD Prediction at MCI Stage by 18F-FDG Brain PET Imaging

✓ Peer-reviewed alzhub usefulness score 49 out of 100. IEEE transactions on medical imaging 2020-12-29

Alzheimer's Disease (AD), one of the main causes of death in elderly people, is characterized by Mild Cognitive Impairment (MCI) at prodromal stage. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuroinflammation and protein pathology in Parkinson's disease dementia

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Acta neuropathologica communications 2020-12-03

Parkinson's disease dementia is neuropathologically characterized by aggregates of α-synuclein (Lewy bodies) in limbic and neocortical areas of the brain with additional involvement of Alzheimer's disease-type pathology. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

β-amyloid and tau drive early Alzheimer's disease decline while glucose hypometabolism drives late decline

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Communications biology 2020-07-06

Clinical trials focusing on therapeutic candidates that modify β-amyloid (Aβ) have repeatedly failed to treat Alzheimer's disease (AD), suggesting that Aβ may not be the optimal target for treating AD. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2020-01-06

New personalized endpoints that are clinically meaningful to individuals and their families should be developed. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of C9orf72 expansion carriers

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Molecular neurodegeneration 2020-01-30

In blood from C9orf72 expansion carriers, we found elevated methylation levels, reduced expression levels, and unstable expansions that tend to contract in successive generations, arguing against anticipation. 5 key findings →

Participants: 75 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Mechanisms of Pathogenic Tau and Aβ Protein Spreading in Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Frontiers in aging neuroscience 2020-08-27

Alzheimer's disease (AD) is pathologically defined by extracellular accumulation of amyloid-β (Aβ) peptides generated by the cleavage of amyloid precursor protein (APP), strings of hyperphosphorylated Tau proteins accumulating inside neurons known as neurofibrillary tangles (NFTs) and neuronal loss. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events